FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912832282> ?p ?o ?g. }

• W2912832282 abstract "450 Background: The role of neoadjuvant systemic therapy in the management of body and tail pancreatic ductal adenocarcinoma (PDAC) is unknown. The aim of our study was to investigate the outcomes associated with neoadjuvant therapy for early stage body and tail PDAC. Methods: The National Cancer Database (NCDB) was queried for stage I and II body and tail PDAC between 2006-2014. Groups were defined according to treatment sequencing strategies into an upfront resection group (UR), resection followed by adjuvant therapy (R+AT), neoadjuvant therapy followed by resection (NAT+R), and neoadjuvant therapy followed by resection and adjuvant therapy (NAT+R+AT). Patients who underwent neoadjuvant therapy followed by resection were matched by propensity score with patients who underwent upfront resection. Overall survival was compared using Kaplan-Meier method and Cox proportional hazards regression model. Results: 441 patients received NAT+R with or without AT compared to 1323 patient who underwent UR with or without AT. NAT+R had lower pathologic stage, lymph node positivity and a higher rate of margin negative resections compared to the matched UR cohort. In the propensity matched cohort, the median survival (MS) was higher in the neoadjuvant (NAT+R/NAT+R+AT) group compared to the upfront resection (UR/R+AT) group (28.6 vs. 22.9 mo; p<0.001). When further stratified by treatment sequencing the MS was longer in a NAT+R+AT cohort compared to the R+AT group (36.0 vs. 25.3 mo; p<0.05) (Table). However, there was no difference in MS between R+AT and NAT+R cohorts. On multivariable analysis, receipt of NAT represented an independent factor for survival (NAT+R+AT HR 0.41, 95% CI 0.32-0.54; NAT+R HR, 0.53, 95% CI 0.44-0.64; R+AT HR 0.61, 95% CI 0.53-0.70). Conclusions: There appears to be a survival benefit with neoadjuvant systemic therapy in patients with early stage body and tail PDAC. A systemic perioperative treatment sequencing approach (NAT+R+AT) appears to have the greatest survival benefit. [Table: see text]" @default.
• W2912832282 created "2019-02-21" @default.
• W2912832282 creator A5015987197 @default.
• W2912832282 creator A5024718359 @default.
• W2912832282 creator A5038487788 @default.
• W2912832282 creator A5046825020 @default.
• W2912832282 creator A5053633083 @default.
• W2912832282 creator A5079014185 @default.
• W2912832282 date "2019-02-01" @default.
• W2912832282 modified "2023-09-24" @default.
• W2912832282 title "Neoadjuvant therapy for body and tail pancreatic adenocarcinoma: Propensity score matched analysis using the National Cancer Database." @default.
• W2912832282 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.450" @default.
• W2912832282 hasPublicationYear "2019" @default.
• W2912832282 type Work @default.
• W2912832282 sameAs 2912832282 @default.
• W2912832282 citedByCount "0" @default.
• W2912832282 crossrefType "journal-article" @default.
• W2912832282 hasAuthorship W2912832282A5015987197 @default.
• W2912832282 hasAuthorship W2912832282A5024718359 @default.
• W2912832282 hasAuthorship W2912832282A5038487788 @default.
• W2912832282 hasAuthorship W2912832282A5046825020 @default.
• W2912832282 hasAuthorship W2912832282A5053633083 @default.
• W2912832282 hasAuthorship W2912832282A5079014185 @default.
• W2912832282 hasConcept C121608353 @default.
• W2912832282 hasConcept C126322002 @default.
• W2912832282 hasConcept C143998085 @default.
• W2912832282 hasConcept C146357865 @default.
• W2912832282 hasConcept C151730666 @default.
• W2912832282 hasConcept C17923572 @default.
• W2912832282 hasConcept C2777982462 @default.
• W2912832282 hasConcept C2778292576 @default.
• W2912832282 hasConcept C2780210213 @default.
• W2912832282 hasConcept C50382708 @default.
• W2912832282 hasConcept C530470458 @default.
• W2912832282 hasConcept C71924100 @default.
• W2912832282 hasConcept C72563966 @default.
• W2912832282 hasConcept C86803240 @default.
• W2912832282 hasConceptScore W2912832282C121608353 @default.
• W2912832282 hasConceptScore W2912832282C126322002 @default.
• W2912832282 hasConceptScore W2912832282C143998085 @default.
• W2912832282 hasConceptScore W2912832282C146357865 @default.
• W2912832282 hasConceptScore W2912832282C151730666 @default.
• W2912832282 hasConceptScore W2912832282C17923572 @default.
• W2912832282 hasConceptScore W2912832282C2777982462 @default.
• W2912832282 hasConceptScore W2912832282C2778292576 @default.
• W2912832282 hasConceptScore W2912832282C2780210213 @default.
• W2912832282 hasConceptScore W2912832282C50382708 @default.
• W2912832282 hasConceptScore W2912832282C530470458 @default.
• W2912832282 hasConceptScore W2912832282C71924100 @default.
• W2912832282 hasConceptScore W2912832282C72563966 @default.
• W2912832282 hasConceptScore W2912832282C86803240 @default.
• W2912832282 hasLocation W29128322821 @default.
• W2912832282 hasOpenAccess W2912832282 @default.
• W2912832282 hasPrimaryLocation W29128322821 @default.
• W2912832282 hasRelatedWork W2037608659 @default.
• W2912832282 hasRelatedWork W2742582606 @default.
• W2912832282 hasRelatedWork W2743061229 @default.
• W2912832282 hasRelatedWork W2758979851 @default.
• W2912832282 hasRelatedWork W2801234890 @default.
• W2912832282 hasRelatedWork W2912832282 @default.
• W2912832282 hasRelatedWork W3024417375 @default.
• W2912832282 hasRelatedWork W3154966794 @default.
• W2912832282 hasRelatedWork W4286270419 @default.
• W2912832282 hasRelatedWork W2184986579 @default.
• W2912832282 isParatext "false" @default.
• W2912832282 isRetracted "false" @default.
• W2912832282 magId "2912832282" @default.
• W2912832282 workType "article" @default.